Placebo News and Research

RSS

Linagliptin safe and effective for long-term management of type 2 diabetes

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication.

23 Jul 2012

Egg allergy treatment for children: an interview with Dr Robert Wood

The tendency to get allergies is a fairly general one, which is mostly inherited – it tends to run in families. There are several foods that are most common for children to become allergic to: milk, egg and peanuts in most countries are the most common food allergies.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

21 Jul 2012

Phosphate binders may cause unexpected harm to blood vessels in patients with CKD

Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as strongly effective as once thought, and may cause unexpected harm to blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

20 Jul 2012

Knee surgery blood loss reduced with single tranexamic acid dose

A single intraoperative dose of tranexamic acid is effective at reducing blood loss in patients undergoing minimally invasive total knee arthroplasty, research suggests.

20 Jul 2012

Unexplained fatigue in women: start iron supplements

Iron deficiency may be underdiagnosed in women of child-bearing age who report considerable fatigue, say researchers whose randomized controlled trial results show a significant reduction in fatigue after women took iron supplements.

20 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Iron deficiency in women ‘may be under-recognized’

Iron deficiency may be an under-recognized cause of fatigue in women, say investigators who report that iron supplementation reduced symptoms of fatigue in women who were not anemic but had low ferritin levels.

19 Jul 2012

New hope for children with egg allergy

Doctors currently have only one recommendation for people allergic to eggs: avoid eggs completely. But researchers at the University of North Carolina School of Medicine recently found promise in doing just the opposite. Eating small amounts of egg every day for many months lowered the threshold for allergic reactions in 75 percent of egg-allergic children; 28 percent were able to incorporate egg into their regular diets after two years on the treatment.

19 Jul 2012

Egg allergies in children can be treated with oral immunotherapy

Giving children with egg allergies increasingly higher doses of the very food they are allergic to can eliminate or ease reactions in most of them, according to results from a federally funded study conducted at Johns Hopkins Children's Center and four other U.S. institutions.

19 Jul 2012

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Acucela Inc., a clinical stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 3 clinical trial to evaluate rebamipide ophthalmic suspension in patients with dry eye syndrome.

19 Jul 2012

Angion Biomedica initiates BB3 Phase II trial in heart attack

Angion Biomedica Corp. announced today that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction).

19 Jul 2012

Silymarin does not provide greater benefit for patients with chronic HCV infection

Use of the botanical product silymarin, an extract of milk thistle that is commonly used by some patients with chronic liver disease, did not provide greater benefit than placebo for patients with treatment-resistant chronic hepatitis C virus (HCV) infection, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Placebo News and Research

Linagliptin safe and effective for long-term management of type 2 diabetes

Egg allergy treatment for children: an interview with Dr Robert Wood

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Phosphate binders may cause unexpected harm to blood vessels in patients with CKD

Knee surgery blood loss reduced with single tranexamic acid dose

Unexplained fatigue in women: start iron supplements

Silymarin does not offer significant improvements for patients with HCV

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Iron deficiency in women ‘may be under-recognized’

New hope for children with egg allergy

Egg allergies in children can be treated with oral immunotherapy

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Angion Biomedica initiates BB3 Phase II trial in heart attack

Silymarin does not provide greater benefit for patients with chronic HCV infection

Vivus receives FDA approval for Qsymia to manage chronic weight

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News